资讯汇总 [table_Header]2026.02.09 【ESG 投资周报】本月新发绿色债券 24 只，流 动性环比宽松 2026.02.02 【行业 ESG 周报】沪深北交易所修订可持续发展 报告编制指南，三部门联合发文促工业园区绿色 发展 2026.02.02 【ESG 投资周报】本月新发绿色债券 80 只，银 行理财稳步发行 2026.01.26 【行业 ESG 周报】五部门印发指导意见支撑零碳 工厂建设，我国新型自然保护地体系初步建成 2026.01.26 【ESG 投资周报】本月新发 ESG基金 1 只，绿色 债券稳步发行 2026.01.19 【ESG 投资周报】本月新发 ESG 基金 2 只，流动性环比收窄 产业研究中心 摘要： | [Table_Authors] | | | --- | --- | | | 赵子健(分析师) | | | 021-38032292 | | | zhaozijian@gtht.com | | 登记编号 | S0880520060003 | | | 王佳(分析师) | | | 010-83939781 | | | wangjia7@gtht.com | | 登记编 ...

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [2][6]. Core Insights - The medical device procurement scale is experiencing a partial decline due to high base effects, but there are opportunities in the surgical robot market [2]. - The report emphasizes that the ongoing implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, recommending companies that are likely to benefit from these policies [4]. - The report highlights that the four ministries jointly issued a notice in 2024 aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, which is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [6]. Summary by Sections Investment Recommendations - The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment upgrade policies, including Mindray Medical, United Imaging, Kaili Medical, Aohua Endoscopy, and Jingfeng Medical-B. It also suggests paying attention to MicroPort Scientific-B [6]. Monthly Procurement Data - In January 2026, the procurement scale for new devices showed a year-on-year decline: MR down 22.6%, CT down 25.6%, DR down 18.2%, ultrasound down 10.1%, while endoscopy grew by 1.1%, and surgical robots declined by 20.1%. Company-specific performance showed United Imaging MR down 36.5%, United Imaging CT up 8.5%, Mindray ultrasound up 10.9%, Kaili ultrasound down 14.8%, Kaili endoscopy up 55.4%, and Aohua endoscopy down 11.7% [6]. Policy Impact - The report discusses the release of a guideline by the National Healthcare Security Administration on January 20, 2026, which establishes a unified pricing project for surgical robots, expected to accelerate the penetration and application of robotic surgery technology [6].

| | | | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 秦和平(分析师) | 0755-23976666 | qinheping@gtht.com | S0880523110003 | | | | 高翩然(分析师) | 0755-80305701 | gaopianran@gtht.com | S0880525040066 | [当前价格 Table_CurPrice] (美元)： | 82.20 | 本报告导读： WBD 头部 IP 储备叠加工业化内容生产体系构成核心竞争壁垒，并表后有望大幅降 低外购版权费用，提升内容商业价值挖掘空间。 投资要点： | 财务摘要(百万美元) | 2024 | 2025 | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 39001 | 45183 | 51137 | 57626 | 64556 | | (+/-)% ...

Market Performance - The new stock index and the near-term new stock index fell by 2.01% and 2.23% respectively during the first week of February 2026[7] - The market experienced significant adjustments, with the technology sector leading the decline, particularly in the non-ferrous metals and electronic sectors[7] New Stock Listings - The first unprofitable new stock of the year, Beixin Life, was listed, achieving an average first-day increase of 185.65%[1] - Two new stocks contributed to A1/A2/B class investors' single-account full returns of 17.80/9.44/7.90 thousand yuan, enhancing the yield rates for 500 million scale accounts by 0.36‰/0.19‰/0.16‰[41] Trading Activity - Trading activity in the new stock sector continued to decline, with turnover rates for the new stock index and near-term new stock index dropping by 2.10 percentage points and 2.25 percentage points respectively[21] - The net active selling in the new stock sector was 2.936 billion yuan, a decrease of 3.540 billion yuan from the previous week[23] Valuation Changes - The new stock index PE (TTM) increased by 1.76, while the near-term new stock index PE (TTM) decreased by 23.73[14] - The latest PE (TTM) values for the new stock index and near-term new stock index were 80.0X and 159.7X, corresponding to historical percentile levels of 83.8% and 99.2% respectively[14] Upcoming Unlocks - In the second week of February, three new stocks are expected to unlock, with a total unlock scale of 254 million yuan, maintaining low levels[35]

股票研究 /[Table_Date] 2026.02.09 权益市场火热，居民边际配置权益资产 投资银行业与经纪业 [Table_Industry] 2025 年 12 月财富管理月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 刘欣琦(分析师) | 021-38676647 | liuxinqi@gtht.com | S0880515050001 | | 张轩铭(分析师) | 021-38038437 | zhangxuanming@gtht.com | S0880526020001 | | 吴浩东(分析师) | 010-83939780 | wuhaodong@gtht.com | S0880524070001 | 本报告导读： [Table_Invest] 评级： 增持 [Table_Report] 相关报告 投资银行业与经纪业《业绩基准新规落地，助推 行业长期发展》2026.01.24 投资银行业与经纪业《零售及自营业务驱动全年 高增》2026.01.20 投资银行业与经纪业《完善监管制度，打开稳步 发展长期空间 ...

Group 1: Precision Medicine and Robotics - The report highlights Jingfeng Medical-B as a leader in surgical robotics in China, driving advancements in surgical procedures through continuous technological innovation, with rapid growth in global clinical surgeries and domestic sales [2][3] - The company is projected to achieve revenues of 432 million, 811 million, and 1.236 billion yuan from 2025 to 2027, with a target price of 73.20 yuan for 2026 based on a 35X PS valuation [3] - Jingfeng Medical has established a comprehensive surgical solution with its innovative multi-port and single-port robotic systems, becoming the first in China and the second globally to obtain regulatory approval for multiple robotic systems [3][4] Group 2: Market Performance and Sales Growth - In 2024, Jingfeng Medical sold 20 multi-port surgical robots, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces in China [4] - The company's total revenue is expected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, with a significant rise from 30 million yuan in the first half of 2024 to 149 million yuan in the first half of 2025 [4] - The report indicates that Jingfeng Medical's international expansion has led to explosive growth in overseas orders, with 72 out of 118 signed global sales agreements for core products being from overseas markets [5] Group 3: Precision Manufacturing and Emerging Industries - The report covers Xingrui Technology as a leading precision manufacturing enterprise in China, focusing on automotive electronics and actively expanding into emerging industries, with a target price of 32.11 yuan [6][8] - Revenue projections for Xingrui Technology are 1.626 billion, 1.980 billion, and 2.482 billion yuan from 2025 to 2027, with an expected EPS of 0.48, 0.69, and 0.95 yuan respectively [6] - The company has established a robust product matrix, including electronic connectors and structural components, with applications in new energy vehicle systems and consumer electronics, enhancing its competitive advantage in the automotive electronics sector [7] Group 4: Strategic Partnerships and Market Expansion - Xingrui Technology has formed strategic partnerships to expand into the liquid cooling industry, collaborating with Green Cloud to develop advanced technologies and products for data centers [8] - The company has a strong customer base, collaborating with renowned brands in consumer electronics and new energy sectors, and has established a global business layout with factories in multiple locations [7][8] - The report emphasizes the potential for Xingrui Technology to benefit from the growing demand for liquid cooling solutions driven by energy efficiency upgrades in data centers [8]

Market Performance - The new stock index and the near-term new stock index fell by 2.01% and 2.23% respectively during the first week of February 2026[7] - The market experienced significant adjustments, with the technology sector leading the decline, particularly in the non-ferrous metals and electronic sectors[7] New Stock Listings - The first unprofitable new stock of the year, Beixin Life, was listed, achieving an average first-day increase of 185.65%[1] - Two new stocks contributed to A1/A2/B class investors' single-account full returns of 17.80/9.44/7.90 thousand yuan, enhancing the yield rates for a 500 million yuan scale account by 0.36‰/0.19‰/0.16‰[41] Trading Activity - Trading activity in the new stock sector continued to decline, with turnover rates for the new stock index and near-term new stock index dropping by 2.10 percentage points and 2.25 percentage points respectively[21] - The net active selling in the new stock sector amounted to 2.936 billion yuan, a decrease of 3.540 billion yuan from the previous week[23] Valuation Changes - The new stock index PE (TTM) increased by 1.76, while the near-term new stock index PE (TTM) decreased by 23.73[14] - The latest PE (TTM) values for the new stock index and near-term new stock index were 80.0X and 159.7X, corresponding to historical percentile levels of 83.8% and 99.2% respectively[14]

Investment Rating - The investment rating for the company is "Cautious Accumulate" [4][12]. Core Views - The report indicates that the home appliance industry is facing significant pressure due to weak demand and intense competition, leading to challenges in revenue and performance [2][12]. - The company is expected to experience a substantial decline in net profit for 2025, with estimates ranging from 0.10 to 0.15 billion yuan, representing a year-on-year decrease of approximately 86.42% to 90.95% [12]. - The report highlights that the decline in performance is primarily due to weak market demand for integrated stoves and increased competition, resulting in reduced sales volume and order intake [12]. Financial Summary - Total revenue is projected to decline from 1.673 billion yuan in 2023 to 439 million yuan in 2025, reflecting a decrease of 47.5% [10]. - Net profit attributable to the parent company is expected to drop from 464 million yuan in 2023 to 14 million yuan in 2025, a decline of 86.9% [10]. - Earnings per share (EPS) is forecasted to decrease from 0.72 yuan in 2023 to 0.02 yuan in 2025, with a subsequent recovery to 0.07 yuan in 2026 and 0.14 yuan in 2027 [10][12]. Market Data - The company's target price is set at 10.50 yuan, based on a price-to-earnings (PE) ratio of 150x for 2026 [4][12]. - The stock has a 52-week price range of 6.74 to 10.20 yuan, with a total market capitalization of 6.17 billion yuan [5][12]. - The company has a net asset value per share of 2.29 yuan and a current price-to-book (P/B) ratio of 4.2 [6][10].

- The report discusses the construction of **Smart Beta portfolios** based on three styles: value, growth, and small-cap. These portfolios are designed with the objectives of high beta elasticity and long-term stable excess returns. The portfolios include "50 portfolios" and "balanced 50 portfolios" for each style[5] - The **Value Smart Beta portfolios** include the "Value 50 Portfolio" and the "Value Balanced 50 Portfolio". Their weekly returns were 0.19% and 0.22%, respectively, with annual returns of 0.70% and 8.68% since the beginning of the year[3][6][8] - The **Growth Smart Beta portfolios** include the "Growth 50 Portfolio" and the "Growth Balanced 50 Portfolio". Their weekly returns were -2.53% and -1.95%, respectively, with annual returns of 1.29% and 6.55% since the beginning of the year[3][6][16] - The **Small-Cap Smart Beta portfolios** include the "Small-Cap 50 Portfolio" and the "Small-Cap Balanced 50 Portfolio". Their weekly returns were 1.71% and -0.52%, respectively, with annual returns of 11.72% and 9.49% since the beginning of the year[3][6][20] - The **performance metrics** for these portfolios include absolute returns, excess returns relative to their benchmarks, and maximum relative drawdowns. For example, the "Small-Cap 50 Portfolio" achieved an excess return of 3.45% over the benchmark "CNI 2000" index during the week, with a maximum relative drawdown of 3.08%[6][20]

Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 262.35 CNY, compared to the current price of 221.01 CNY [5]. Core Insights - The company is expected to benefit from the rapid growth in the optical communication market driven by AI computing demands, with projected revenues of 5.92 billion CNY, 7.68 billion CNY, and 9.81 billion CNY for 2025-2027, respectively [10]. - The net profit forecast for the same period is 870 million CNY, 1.28 billion CNY, and 1.71 billion CNY, with EPS of 0.68 CNY, 0.99 CNY, and 1.32 CNY [10]. - The global optical module market is projected to reach approximately 25 billion USD by 2029, with a CAGR of 15% from 2023 to 2029, primarily driven by strong demand from AI applications [10]. Financial Summary - Total revenue is forecasted to be 340 million CNY in 2023, increasing to 981 million CNY by 2027, reflecting a growth rate of 31% in 2024 and 33% in 2025 [4]. - Net profit attributable to the parent company is expected to rise from 42 million CNY in 2023 to 171 million CNY in 2027, with a significant increase of 66.5% in 2024 [4]. - The company’s PE ratio is projected to decrease from 686.28 in 2023 to 167.50 in 2027, indicating improving valuation metrics [4]. Company Overview - The company, established in October 2013, specializes in the research, production, and sales of precision optical components, fiber optic devices, and optical testing instruments, with applications in optical communication and fiber lasers [14]. - The company has a strong technical foundation with multiple core technology platforms, including optical film technology and precision optical technology, enabling it to provide customized solutions [14][15]. - The management team has extensive experience in the optical electronics field, with key personnel holding advanced degrees from prestigious institutions [20][21]. Market Trends - The demand for AI computing is driving the growth of the optical communication market, with OCS (Optical Circuit Switching) technology being recognized for its value in low-latency and high-bandwidth applications [10]. - The company is expanding its product offerings in emerging fields such as quantum information research, biomedical applications, and consumer optics, which are expected to contribute to revenue growth [10][29].